Skip to main content
SpringerLink
Log in

Treatment of Graves’ Disease

  • Reference work entry
  • First Online:
Thyroid Diseases

Part of the book series: Endocrinology ((ENDOCR))

  • 2100 Accesses

Abstract

Treatment of hyperthyroidism due to Graves’ disease relies on the use of antithyroid drugs, radioiodine treatment, or thyroidectomy. None of these treatments are perfect, because they are not therapies targeting pathogenic mechanisms of the disease. Selection of either treatment is based on several criteria, but the choice should be shared with the informed patient. The major extrathyroidal manifestation of Graves’ disease, i.e., Graves’ orbitopathy, when moderate and active should be treated with high doses of intravenous glucocorticoids. This chapter provides an overview of treatment options for both hyperthyroidism and extrathyroidal manifestations, underscoring advantages and disadvantages of therapies, as well as preferred strategies in case of under particular circumstances, such as pregnancy and childhood.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 329.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol. 2005;153:489–98.

    Article  CAS  PubMed  Google Scholar 

  • Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcome in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015;100:451–9.

    Article  CAS  PubMed  Google Scholar 

  • Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96:592–9.

    Article  CAS  PubMed  Google Scholar 

  • Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724–34.

    Article  CAS  PubMed  Google Scholar 

  • Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;38:691–700.

    Article  CAS  Google Scholar 

  • Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.

    Article  CAS  PubMed  Google Scholar 

  • Bartalena L, Krassas GE, Wiersinga WM, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–63.

    Article  CAS  PubMed  Google Scholar 

  • Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest. 2015;38:481–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016a;5:9–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bartalena L, Burch HB, Burman HD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016b;84:115–20.

    Article  CAS  Google Scholar 

  • Bartalena L, Chiovato L, Vitti P. Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any). J Endocrinol Invest. 2016c;39:1105–14.

    Article  CAS  PubMed  Google Scholar 

  • Bartalena L, Masiello E, Magri F, Veronesi G, Bianconi E, Zerbini F, et al. The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J Endocrinol Invest. 2016d;39:1445–1451.

    Article  CAS  PubMed  Google Scholar 

  • Biondi B, Bartalena L, Coopper DS, Hegedus L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4:149–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab. 2013;98:1869–82.

    Article  CAS  PubMed  Google Scholar 

  • Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95:201–8.

    Article  CAS  Google Scholar 

  • Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.

    Article  CAS  PubMed  Google Scholar 

  • Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol. 2003;149:485–92.

    Article  CAS  PubMed  Google Scholar 

  • Bowman P, Osborne NJ, Sturley R, Vaidya B. Carbimazole embriopathy: implications for the choice of antithyroid drugs in pregnancy. Q J Med. 2012;105:189–93.

    Article  CAS  Google Scholar 

  • Brandt F, Green A, Hegedus L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–7.

    Article  CAS  PubMed  Google Scholar 

  • Brandt F, Thvilum M, Almind D, et al. Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013a;23:408–13.

    Article  PubMed  Google Scholar 

  • Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidsm: a nationwide register-based study. PLoS One. 2013b;8:e66711.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Brito JP, Castaneda-Guarderas A, Gionfriddo NR, Singh Ospina N, Maraka S, Dean DS, et al. Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves’ disease. Thyroid. 2015;25:1191–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Brito JP, Stephanie S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham R, et al. Antithyroid drugs – the most common treatment for Graves’ disease in the United states: a nationwide population-based study. Thyroid. 2016;26:1144–5.

    Article  PubMed  Google Scholar 

  • Burch HB, Cooper DS. Management of Graves disease. A review. JAMA. 2015;314:2544–54.

    Article  CAS  PubMed  Google Scholar 

  • Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–58.

    Article  CAS  PubMed  Google Scholar 

  • Ceccarelli C, Canale D, Battisti P, Cagliaresi C, Moscatelli A, Gavioli S, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf). 2006;65:446–52.

    Article  CAS  Google Scholar 

  • Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905–17.

    Article  CAS  PubMed  Google Scholar 

  • Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab. 2009;94:1881–2.

    Article  CAS  PubMed  Google Scholar 

  • De Leo S, Braverman LE. Hyperthyroidism. Lancet. 2016;338:906–18.

    Article  CAS  Google Scholar 

  • DeGroot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2543–65.

    Article  CAS  Google Scholar 

  • Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70.

    Article  CAS  PubMed  Google Scholar 

  • Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95:2227–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Erbil Y, Giriş M, Salmaslioglu A, Ozluk Y, Barbaros U, Yanik BT, Kapran Y, Abbasoglu SD, Ozarmagan S. The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves’ disease. Surgery. 2008;143:216–25.

    Article  PubMed  Google Scholar 

  • Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712–8.

    Article  CAS  PubMed  Google Scholar 

  • Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid. 1999;9:29–31.

    Article  CAS  PubMed  Google Scholar 

  • Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Am Surg Oncol. 2013;20:660–7.

    Article  Google Scholar 

  • Gianetti E, Russo L, Orlandi F, Chiovato L, Giusti M, Benvenga S, et al. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest. 2015;38:977–85.

    Article  CAS  PubMed  Google Scholar 

  • Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ disease: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf). 2013;79:739–46.

    Google Scholar 

  • Havgaard Kjaer R, Smedegard Hansen M, Hansen D. Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998–2012. Horm Res Paediatr. 2015;84:102–7.

    Article  CAS  PubMed  Google Scholar 

  • Hegedus L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf); 2011;74:1–8.

    Article  CAS  Google Scholar 

  • Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid disease: a meta-analysis. Endocr Relat Cancer. 2012;19:645–55.

    Article  CAS  PubMed  Google Scholar 

  • In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves’ disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209:170–9.

    Article  PubMed  Google Scholar 

  • Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16:415–22.

    Article  CAS  PubMed  Google Scholar 

  • Kahaly GJ, Rosler HP, Pitz S, Hommel G. Low- versus high-dose orbital radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85:102–8.

    PubMed  CAS  Google Scholar 

  • Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.

    Article  CAS  PubMed  Google Scholar 

  • Kim HJ, Kim BH, Yan JS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol. 2001;96:165–9.

    Article  CAS  PubMed  Google Scholar 

  • Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid drug use and neonatal outcomes with an integrated healthcare delivery system. Thyroid. 2013;23:758–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • La Cour JL, Jensen LT, Vej-Hansen A, Nygaard B. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol. 2015;172:771–8.

    Article  CAS  PubMed  Google Scholar 

  • Lazarus JH, Bartalena L, Marcocci C, Kahaly GJ, Krassas G, Wiersinga WM. Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. J Endocrinol Invest. 2010;33:409–13.

    Article  CAS  PubMed  Google Scholar 

  • Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid. 2007;17:357–62.

    Article  CAS  PubMed  Google Scholar 

  • Linding Andersen S, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373–81.

    Article  CAS  Google Scholar 

  • Linding Andersen S, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;10:1533–40.

    Article  CAS  Google Scholar 

  • Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective. single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562–7.

    PubMed  CAS  Google Scholar 

  • Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–32.

    Article  CAS  PubMed  Google Scholar 

  • Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen, Orgiazzi J, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166:247–53.

    Article  CAS  PubMed  Google Scholar 

  • Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–6.

    Article  CAS  PubMed  Google Scholar 

  • Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321–3.

    Article  CAS  PubMed  Google Scholar 

  • Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest. 2013;36:444–9.

    Google Scholar 

  • Piantanida E, Lai A, Sassi L, Gallo D, Spreafico M, Tanda ML, Bartalena L. Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res. 2015;47:767–72.

    Article  CAS  PubMed  Google Scholar 

  • Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321:1353–9.

    Article  CAS  PubMed  Google Scholar 

  • Riedl M, Kolbe E, Kampmann E, Kramer I, Kahaly GJ. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves’ orbitopathy. J Endocrinol Invest. 2015;38:177–82.

    Article  CAS  PubMed  Google Scholar 

  • Rivkees SA. Controversies in the management of Graves’ disease in children. J Endocrinol Invest. 2016;39:1247–57.

    Article  CAS  PubMed  Google Scholar 

  • Rivkees SA, Szarfman A. Dissimilar hepatoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95:3260–7.

    Article  CAS  PubMed  Google Scholar 

  • Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364:542–50.

    Article  CAS  PubMed  Google Scholar 

  • Ross DS, Burch HB, Copper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicisos. Thyroid. 2016;26:1343–421.

    Article  PubMed  Google Scholar 

  • Ruiz JK, Rossi GV, Vallejos HA, Brener RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother. 2003;37:224–8.

    Article  PubMed  Google Scholar 

  • Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab. 2015;100:3710–7.

    Article  CAS  PubMed  Google Scholar 

  • Salvi M, Vannucchi G, Beck-Peccoz P. Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:4291–9.

    Article  CAS  PubMed  Google Scholar 

  • Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31.

    Article  CAS  PubMed  Google Scholar 

  • Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;69:479–90.

    Article  PubMed  Google Scholar 

  • Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014;24:1515–23.

    Article  CAS  PubMed  Google Scholar 

  • Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.

    Article  PubMed  Google Scholar 

  • Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, et al. Intravenous glucocorticoid therapy for Graves’ ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol. 2015a;172:269–76.

    Article  CAS  PubMed  Google Scholar 

  • Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, et al. Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest. 2015b;38:661–8.

    Article  CAS  PubMed  Google Scholar 

  • Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375:1552–65.

    Article  PubMed  Google Scholar 

  • Sosa IA, Tuggle CT, Wabg TS, Thomas DC, Boudourakis L, Rivkees S, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–65.

    Article  CAS  PubMed  Google Scholar 

  • Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081–125.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stan M, Salvi M. Rituximab therapy for Graves’ orbitopathy. Lessons from randomized clinical trials. Eur J Endocrinol. 2017;176:R101–9.

    Google Scholar 

  • Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–41.

    Article  CAS  PubMed  Google Scholar 

  • Stiggelbout AM, Van der Weijden T, De Wit MPT, Frosch D, Légare F, Montori V, et al. Shared decision making: really putting patients at the centre of healthcare. Br Med J. 2012;344:e256.

    Article  CAS  Google Scholar 

  • Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98:3671–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494–7.

    Article  CAS  PubMed  Google Scholar 

  • Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:3857–65.

    Article  CAS  PubMed  Google Scholar 

  • Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98:1443–9.

    Article  CAS  PubMed  Google Scholar 

  • Ting HH, Brito JP, Montori VM. Shared decision making. Science and action. Circ Cardiovasc Qual Outcomes. 2014;7:323–7.

    Article  PubMed  Google Scholar 

  • Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. J Clin Endocrinol Metab. 1996;81:2986–93.

    PubMed  Google Scholar 

  • Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. Thyroid associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700–7.

    Article  CAS  PubMed  Google Scholar 

  • Tun NN, Beckett G, Zammitt NN, Strachan MW, Seckl JR, Gibb FW. Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid. 2016;26:1004–9.

    Article  CAS  PubMed  Google Scholar 

  • Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008;68:814–20.

    Article  Google Scholar 

  • Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.

    Article  CAS  PubMed  Google Scholar 

  • Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Watanabe N, Narimatsu H, Yoshimura Noh J, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves’ disease. J Clin Endocrinol Metab. 2012;97:E49–53.

    Article  CAS  PubMed  Google Scholar 

  • Weetman AP. Graves’ disease following immune reconstitution of immunomodulatory treatment: should we manage it any differently? Clin Endocrinol (Oxf). 2014;80:629–32.

    Article  CAS  Google Scholar 

  • Wiersinga W. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2016; doi:10.1016/S2213-8587(16)30046-8 (e-pub ahead of print).

    Google Scholar 

  • Yang J, Li LF, Xu Q, Zhang J, Weng W-W, Zhu YI, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25:278–83.

    Article  CAS  PubMed  Google Scholar 

  • Yang J, Zhu Y-J, Zhong JJ, Zhang J, Weng W-W, Z-f L, et al. Characteristics of drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid. 2016;26:627–33.

    Article  CAS  PubMed  Google Scholar 

  • Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Seiya K, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–403.

    Article  CAS  PubMed  Google Scholar 

  • Zang S, Ponto KA, Kahaly GJ. Clinical Review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–32.

    Article  CAS  PubMed  Google Scholar 

  • Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26:765–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Surgery, University of Insubria, Endocrine Unit, ASST dei Sette Laghi, Ospedale di Circolo, Viale Borri, 57, 21100, Varese, Italy

    Luigi Bartalena

Authors
  1. Luigi Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Bartalena .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, University of Pisa, Pisa, Italy

    Paolo Vitti

  2. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

    Laszlo Hegedüs

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bartalena, L. (2018). Treatment of Graves’ Disease. In: Vitti, P., Hegedüs, L. (eds) Thyroid Diseases. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-45013-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45013-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45012-4

  • Online ISBN: 978-3-319-45013-1

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation